JP2023548073A - 多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法 - Google Patents

多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法 Download PDF

Info

Publication number
JP2023548073A
JP2023548073A JP2023524899A JP2023524899A JP2023548073A JP 2023548073 A JP2023548073 A JP 2023548073A JP 2023524899 A JP2023524899 A JP 2023524899A JP 2023524899 A JP2023524899 A JP 2023524899A JP 2023548073 A JP2023548073 A JP 2023548073A
Authority
JP
Japan
Prior art keywords
antibody
dnabii
biologically active
pila
active fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524899A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022094433A5 (https=
JP2023548073A5 (https=
Inventor
ローレン オー． バカレッツ，
スティーブン ディー． グッドマン，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/364,578 external-priority patent/US12116614B2/en
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2023548073A publication Critical patent/JP2023548073A/ja
Publication of JPWO2022094433A5 publication Critical patent/JPWO2022094433A5/ja
Publication of JP2023548073A5 publication Critical patent/JP2023548073A5/ja
Priority to JP2025247996A priority Critical patent/JP2026034590A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2023524899A 2020-11-01 2021-11-01 多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法 Pending JP2023548073A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025247996A JP2026034590A (ja) 2020-11-01 2025-12-12 多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063108421P 2020-11-01 2020-11-01
US63/108,421 2020-11-01
US17/364,578 US12116614B2 (en) 2020-06-30 2021-06-30 Methods for determining antibiotic sensitivity
US17/364,578 2021-06-30
PCT/US2021/057626 WO2022094433A2 (en) 2020-11-01 2021-11-01 Compositions and methods for preventing, inhibiting, disrupting, or treating a polymicrobial biofilm

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025247996A Division JP2026034590A (ja) 2020-11-01 2025-12-12 多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2023548073A true JP2023548073A (ja) 2023-11-15
JPWO2022094433A5 JPWO2022094433A5 (https=) 2024-10-25
JP2023548073A5 JP2023548073A5 (https=) 2024-10-25

Family

ID=81384466

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023524899A Pending JP2023548073A (ja) 2020-11-01 2021-11-01 多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法
JP2025247996A Pending JP2026034590A (ja) 2020-11-01 2025-12-12 多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025247996A Pending JP2026034590A (ja) 2020-11-01 2025-12-12 多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法

Country Status (7)

Country Link
US (1) US20230406911A1 (https=)
EP (1) EP4237445A4 (https=)
JP (2) JP2023548073A (https=)
CN (1) CN116490778A (https=)
AU (1) AU2021371032A1 (https=)
CA (1) CA3194301A1 (https=)
WO (1) WO2022094433A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023383155A1 (en) * 2022-11-14 2025-05-15 Research Institute At Nationwide Children's Hospital Antibody compositions and methods for disrupting nontuberculous mycobacteria biofilms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528763A (ja) * 2015-07-31 2018-10-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのペプチドおよび抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528763A (ja) * 2015-07-31 2018-10-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのペプチドおよび抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MBIO, vol. Vol.9, No.6, e02423-18, JPN6025038583, 2018, pages 1 - 18, ISSN: 0005825817 *
MOLECULAR MICROBIOLOGY, vol. 93, no. 6, JPN6025038582, 2014, pages 1246 - 1258, ISSN: 0005825816 *
MOLECULAR MICROBIOLOGY, vol. 96, no. 2, JPN6025038584, 2015, pages 276 - 292, ISSN: 0005825818 *

Also Published As

Publication number Publication date
CA3194301A1 (en) 2022-05-05
AU2021371032A1 (en) 2023-05-11
CN116490778A (zh) 2023-07-25
WO2022094433A2 (en) 2022-05-05
WO2022094433A3 (en) 2022-06-30
EP4237445A2 (en) 2023-09-06
US20230406911A1 (en) 2023-12-21
EP4237445A4 (en) 2024-10-02
AU2021371032A9 (en) 2024-05-23
JP2026034590A (ja) 2026-02-27

Similar Documents

Publication Publication Date Title
JP7627255B2 (ja) バイオフィルムを破壊するための抗体組成物
JP7596069B2 (ja) 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
AU2018206560B9 (en) Antibody fragments for the treatment of biofilm-related disorders
JP2024128051A (ja) バイオフィルムの除去のためのｈｍｇｂ１タンパク質誘導体
JP2026034590A (ja) 多微生物性バイオフィルムを防止する、阻害する、破壊する、または処置するための組成物および方法
RU2851685C2 (ru) Композиции антител для разрушения биопленок
JPWO2022094433A5 (https=)
JP2025538154A (ja) 非結核性マイコバクテリアバイオフィルムを破壊するための抗体組成物および方法
JP2025537168A (ja) バイオフィルムおよび好中球細胞外トラップ形成を処置するための組成物および方法
HK40111331A (en) Antibody compositions for disrupting biofilms

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241017

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260326